Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Operating expense | 2.2M | 57.7% |
| Net Income | -2.3M | 55.3% |
| EBITDA | -2.2M | 56.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 3.9M | 18.4% |
| Total Liabilities | 2.3M | 34.8% |
| Total Equity | 1.7M | 24.9% |
| Shares Outstanding | 15M | 108.3% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -3.9M | 67.2% |
| Cash from financing | 2.4M | 211.6% |
EPS
Financial Highlights for TransCode Therapeutics in Q3 '24
Operating Expenses for this period were 2.2M, showing a -57.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.3M, showing a 55.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -2.2M, showing a 56.7% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
